Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.8 -0.28 (-0.72%) Market Cap: 5.66 Bil Enterprise Value: 4.94 Bil PE Ratio: 0 PB Ratio: 19.11 GF Score: 74/100

Ionis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 13, 2021 / 06:00PM GMT
Release Date Price: $36.27 (+0.50%)
David Neil Lebowitz;Elizabeth L. Hougen
Morgan Stanley, Research Division - VP;Ionis

Good afternoon, and welcome to the 19th Annual Morgan Stanley Healthcare Conference. Before I get started, let me just go through the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. (Operator Instructions)

And with that, I'm David Lebowitz, one of the biotechnology analysts here. And I'm happy to have with me from Ionis, CFO, Beth Hougen. Clearly, Ionis is one of the leaders in RNA medicine. Specifically, they have developed antisense technology and have a very, very large clinical pipeline of -- clinical-stage pipeline, over 40 drugs actually in the clinic at this point.

And I guess, Beth, if you could start off just by telling me a little bit about the history of the company, some of the recent transition and strategically, what is Ionis looking to do going forward.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot